Gloucester Pharmaceuticals, Inc.

One Broadway 14th Floor,
Cambridge, Massachusetts 02142
United States,
(617)583-1300

Gloucester develops cancer therapies including Istodax, which was approved by the Food and Drug Administration last month for treatment of cutaneous T-cell lymphoma patients who have had a least one prior systemic therapy. The treatment also has orphan drug designation for treatment of non-Hodgkin's T-cell lymphomas including CTCL and peripheral T-cell lymphoma, as well as fast-track status for PTCL.

Gloucester Pharmaceuticals was acquired by Celgene on January 15, 2010.

Join Mergr to view all 126 acquisitions of medical products companies in 2010, including 21 acquisitions by private equity firms, and 105 by strategics.

Out of 60 sectors in the Mergr database, medical products ranked 11 in number of deals in 2010. The largest medical products acquisition in 2010 was Abraxis BioScience - which was acquired by Celgene for $2.9B.

Join Mergr to view this profile - and discover more medical products acquisitions of companies like Gloucester Pharmaceuticals.


What's Mergr?

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.2K Private Equity Firms
  • 111K M&A Transactions
  • 120K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.7K M&A Advisors
    (Investment Banks and Law Firms)
  • 38K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.